We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Weakness Identified in Armor of Tuberculosis Pathogen

Cylindrical bacterium, colored in purple, all clumped together.
Credit: CDC/ Unsplash
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Mycobacterium tuberculosis (Mtb) is the pathogen that causes tuberculosis (TB), the world’s deadliest infectious disease. Mtb is so successful and harmful because it can adapt to different conditions inside our bodies, allowing it to evade treatment.


By using a computer model to understand Mtb’s adaptations, researchers at Institute for Systems Biology (ISB) have identified a network within Mtb that allows it to tolerate and resist drug therapies. When the network is disrupted, researchers found that Mtb’s cells are unable to properly divide, compromising their cell wall – a key defense mechanism.


“We have quite literally found a chink in Mtb’s armor,” said ISB Professor, Director and Senior Vice President Dr. Nitin Baliga, corresponding author of a paper published by the journal Cell Reports. “We took a systems approach to figure out how this pathogen circumvents treatment, and we found a targetable mechanism that we know helps it deal with stressful conditions.”


The computer model – called EGRIN 2.0 – helps scientists see how Mtb’s genes work together and are affected by their environment. EGRIN 2.0 identified a signaling system called MtrA that helps the pathogen grow in response to signals from a host’s body. The team also found that MtrA decreases the effectiveness of antibiotics used to treat TB.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE
“We believe this clears the way for developing a drug to effectively target and inhibit the essential mechanism of the MtrA signaling system, thus preventing Mtb to resist and tolerate treatment,” said ISB Senior Research Scientist Dr. Eliza Peterson, lead author of the paper. “These insights can also help with finding other drugs and/or multi-drug regimens important for treating TB.”


Peterson, Baliga and team also think the EGRIN 2.0 platform has the capability to identify other Mtb vulnerabilities manifesting in different contexts.


“TB can hide itself, making it difficult to kill,” Baliga said. “This powerful technology helps us build models that show us when and how it is doing that, to find new targets, and to understand how drugs work.”


Reference: Peterson EJR, Brooks AN, Reiss DJ, et al. MtrA modulates Mycobacterium tuberculosis cell division in host microenvironments to mediate intrinsic resistance and drug tolerance. Cell Rep. 2023;42(8). doi: 10.1016/j.celrep.2023.112875


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.